Viracta Therapeutics, Inc.
VIRX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $9,157 | $20,097 | $43,650 | $22,111 |
| - Cash | $13,127 | $13,981 | $12,062 | $12,317 |
| + Debt | $16,911 | $18,819 | $18,857 | $25,556 |
| Enterprise Value | $12,941 | $24,935 | $50,445 | $35,350 |
| Revenue | $0 | $0 | $0 | $738 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$96 | -$110 | $615 |
| % Margin | – | – | – | 83.3% |
| EBITDA | -$9,764 | -$9,037 | -$8,173 | -$12,693 |
| % Margin | – | – | – | -1,719.9% |
| Net Income | -$10,553 | -$9,830 | -$9,141 | -$13,765 |
| % Margin | – | – | – | -1,865.2% |
| EPS Diluted | -0.27 | -0.25 | -0.23 | -0.35 |
| % Growth | -8% | -8.7% | 34.3% | – |
| Operating Cash Flow | -$7,093 | -$9,827 | -$7,849 | -$10,027 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,093 | -$9,827 | -$7,849 | -$10,027 |